Exchange: OTC·Updated 12:15 PM EDT

MUEL News

News
all
press releases
MUEL Q2 Earnings Rise Y/Y Despite Margin Pressure, Backlog Strong
Paul Mueller's Q2 revenues jump 29% y/y, but lower margins weigh on earnings as strong pharmaceutical demand and a healthy backlog support the results.
Zacks
Paul Mueller Q1 Earnings Fall Y/Y on Higher Costs, Revenues Rise
MUEL's Q1 earnings drop sharply y/y despite solid revenue growth, as rising project costs and delays pressure margins and weigh on profitability.
Zacks
Paul Mueller Q4 Earnings Rise Y/Y on Strong Sales, Backlog Growth
MUEL posts strong Q4 results, with rising sales, higher profits and a record backlog, driving shares sharply ahead of the broader market.
Zacks
Zacks Initiates Coverage of MUEL With Neutral Recommendation
Discover why Zacks, the first on Wall Street to initiate coverage, rates MUEL as "Neutral." Explore how Paul Mueller's surging backlog and pharma-driven growth are reshaping its revenue outlook amid key execution risks.
Zacks

Advertisement|Remove ads.